Becker W J
Department of Clinical Neurosciences, Faculty of Medicine, University of Calgary, Alberta, Canada.
Can J Neurol Sci. 2000 May;27(2):111-5.
The triptans represent a major advance in migraine therapy but their cost per dose greatly exceeds that of many older treatments. There is evidence that for a significant proportion of migraine patients these new drugs can show a positive cost benefit and also improve quality of life. Cost benefit would be expected to be greatest in patients with more severe migraine attacks.
